PVLA

SEC Filing Summary: Pieris Pharmaceuticals, Inc. (PIRS)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2024. Pieris Pharmaceuticals, Inc. (Pieris) is a biopharmaceutical company that has discontinued all proprietary research and development (R&D) activities to focus on capturing potential milestone payments from partnered immuno-oncology assets and executing a strategic merger. On July 23, 2024, Pieris entered into a definitive Merger Agreement with Palvella Therapeutics, Inc. (Palvella), under which Pieris will acquire Palvella. The transaction is expected to close in the fourth quarter of 2024, subject to stockholder approval and other conditions.

Key Financial Metrics

Note: Revenue in 2023 included significant milestone and collaboration revenue from partners (Genentech, AstraZeneca, Pfizer) which has ceased in 2024 as obligations were satisfied or agreements terminated.

Material Changes vs. Prior Period

• Revenue Collapse: Revenue dropped to near zero in Q2 2024 compared to $20.1 million in Q2 2023. This is due to the completion of performance obligations under major collaboration agreements (Genentech, AstraZeneca, Pfizer) and the termination of the AstraZeneca and Servier agreements.
• Expense Reduction: Total operating expenses decreased significantly to $4.2 million in Q2 2024 from $18.0 million in Q2 2023. R&D expenses fell to $0.75 million from $14.3 million as the company discontinued all proprietary R&D programs and wound down its German laboratory operations.
• Asset Liquidation: The company sold all property and equipment held for sale in Germany, recovering the net book value and recording a gain of $0.2 million.
• Stock Split: A 1-for-80 reverse stock split was effected on April 22, 2024. All share and per-share data in this filing have been restated retroactively.

Guidance, Outlook, and Risks

• Merger with Palvella: Pieris is merging with Palvella Therapeutics. Pre-merger Pieris stockholders are expected to own approximately 18% of the combined company, while Palvella stockholders will own approximately 82%. The transaction includes a PIPE financing expected to raise approximately $78.9 million.
• Contingent Value Rights (CVRs): Existing Pieris stockholders will receive CVRs entitling them to future payments if Pieris receives milestone or royalty payments from its legacy partnerships (Pfizer, Boston Pharmaceuticals) or tax credits. There is no assurance these payments will occur.
• Liquidity: As of June 30, 2024, Pieris held $19.7 million in cash. Management believes this is sufficient to fund operations through at least the next 12 months, assuming the merger does not close and the company continues its cost-saving strategy.
• Partnership Milestones: Pieris retains potential milestone payments of up to $15.0 million upon first patient dosing in Phase 2 trials and up to $40.0 million upon pivotal trial dosing for its partnered assets (SGN-BB228 and BOS-342).
• Risks: Key risks include the failure to consummate the merger, potential termination fees ($1.0 million payable by Pieris), the possibility that CVRs expire valueless, and the uncertainty of future funding if the merger fails and cash reserves deplete.

Investor Verification Checklist

• Merger Approval: Verify the status of stockholder votes required for the Merger Agreement and the increase in authorized shares.
• PIPE Financing: Confirm the closing of the $78.9 million PIPE financing, which is a condition precedent to the merger.
• Cash Runway: Monitor the burn rate and cash balance to ensure sufficiency if the merger is delayed or terminated.
• Partnership Status: Track the clinical progress of SGN-BB228 (Pfizer) and BOS-342 (Boston Pharmaceuticals) to assess the likelihood of future milestone payments.
• Termination Fees: Review the specific conditions under which Pieris would be liable for the $1.0 million termination fee to Palvella.